How LSD1 affects small cell lung cancer and its treatment
Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer
This study is looking into how a protein called LSD1 affects small cell lung cancer, trying to find out why some tumors respond well to new treatments while others don’t, with the goal of helping doctors create better therapies for patients who need them.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10979170 on NIH RePORTER |
What this research studies
This research investigates the role of the LSD1 protein in small cell lung cancer (SCLC), a type of cancer that currently lacks effective targeted therapies. The study aims to understand why some SCLC tumors respond well to LSD1 inhibitors while others do not, using advanced techniques like CRISPR/Cas9 to identify key mechanisms and potential biomarkers. By uncovering these mechanisms, the research seeks to improve treatment strategies, making LSD1 inhibitors more effective for patients who are resistant to current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with small cell lung cancer, particularly those whose tumors may be sensitive to LSD1 inhibitors.
Not a fit: Patients with other types of lung cancer or those whose tumors are not responsive to LSD1 inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for small cell lung cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promising results with LSD1 inhibitors in small cell lung cancer, indicating that this approach has potential for success.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Oser, Matthew Gilbert — Dana-Farber Cancer Inst
- Study coordinator: Oser, Matthew Gilbert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.